Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: an Illinois Cancer Council Study.
Invest New Drugs
; 7(2-3): 251-3, 1989 Jul.
Article
in En
| MEDLINE
| ID: mdl-2477345
ABSTRACT
Fludarabine Phosphate (FP), the 2-fluoro, 5'phosphate derivative of adenosine arabinoside (ara-A), was studied in 18 patients with advanced renal cell carcinoma. These patients had measurable disease and had not received chemotherapy. FP was administered at a loading dose of 20 mg/m2 followed by a 48-hour infusion at 30 mg/m2/day given every 21 days. There were no complete or partial responses seen. Toxicity was mainly hematologic, with leukopenia most commonly observed. FP given in this manner had no activity in advanced renal cell carcinoma.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Vidarabine Phosphate
/
Arabinonucleotides
/
Carcinoma, Renal Cell
/
Kidney Neoplasms
/
Antimetabolites, Antineoplastic
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Invest New Drugs
Year:
1989
Document type:
Article